REDWOOD CITY, Calif.,
March 11, 2020 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company, today announced that it will release fourth
quarter and annual financial results before market open on
Monday, March 16, 2020. AcelRx
management will host a live webcast and conference call at
8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on March 16, 2020 to discuss the financial results
and provide an update on the company's business.
The webcast is accessible by visiting the Investors page of the
company's website at www.acelrx.com and clicking on the webcast
link on the Investors home page. The webcast will be accompanied by
a slide presentation. A webcast replay will be available on
the AcelRx website for 90 days following the call by visiting the
Investor page of the company's website at www.acelrx.com.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers or (412) 902-4204 for international
callers.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The Company has one
approved product in the U.S., DSUVIA®(sufentanil
sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
one product candidate, Zalviso®(sufentanil sublingual
tablet system, SST system, 15 mcg) being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings. DZUVEO and Zalviso are both approved products in
Europe. Zalviso is an
investigational drug and not approved in the U.S. For additional
information about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-to-announce-fourth-quarter-2019-results-on-monday-march-16th-2020-301021961.html
SOURCE AcelRx Pharmaceuticals, Inc.